Notable updates, news, or analysts actions off of our trading lists.Teladoc price target raised to $260 from $240 at BTIG - $TDOC BTIG analyst David Larsen raised the firm's price target on Teladoc to $260 from $240 and keeps a Buy rating on the shares. Larsen is encouraged that on Monday, Teladoc raised its outlook for 2020 revenue and visit volumes slightly. The analyst says bookings growth are progressing well, he likes the in-sell and cross-sell opportunities, and says revenue growth seems to be on-track.Our Take: Becoming a big healthcare growth play for longer term portfolios. $TDOC, Teladoc Health, Inc. / H1 ViewRay price target raised to $7 from $4 at Piper Sandler - $VRAYPiper Sandler analyst Jason Bednar raised the firm's price target on ViewRay to $7 from $4 and reiterates an Overweight rating on the shares after meeting with management. The analyst came away with increased conviction that the MRIdian use case continues to build.Our Take: Small company with possibilities. Look to play it by using the options, selling puts and/or buy/writes. Speculation stock.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .